Midostaurin治疗FLT3-TKD突变急性髓系白血病:RATIFY试验亚组分析
本文为RATIFY试验的事后亚组分析,评估Midostaurin联合标准化疗在163例FLT3-TKD突变AML患者中的疗效。NPM1突变或CBF重排为独立有利预后因素。
要点
- Midostaurin显著改善FLT3-TKD突变AML的5年无事件生存率。
- 总生存两组无显著差异,无病生存有改善趋势。
- NPM1突变或CBF重排提示更优预后,独立于Midostaurin治疗。
核心结论
- Midostaurin可显著提高FLT3-TKD突变AML患者的5年无事件生存率,但总生存与安慰剂组相似。
- NPM1突变或CBF重排是FLT3-TKD突变AML的独立有利预后因素。
研究设计与样本
- RATIFY试验(CALGB 10603)的事后亚组分析,纳入163例FLT3-TKD突变AML患者。
- 患者随机接受Midostaurin或安慰剂联合标准化疗。
主要发现
- 总生存两组相似。
- NPM1mut/FLT3-TKDmut或CBF重排/FLT3-TKDmut基因型患者总生存显著优于NPM1WT/CBF阴性者,无论是否对造血干细胞移植进行删失。
关键数值与推荐
- 多变量模型调整首次完全缓解后异基因造血干细胞移植作为时间依赖协变量,显示NPM1突变和CBF重排为显著有利因素。
临床怎么用
- 对于FLT3-TKD突变AML患者,可考虑在标准化疗基础上加用Midostaurin以改善无事件生存。
- 应结合NPM1和CBF状态进行预后分层,NPM1突变或CBF重排者预后较好。
局限性
- 为事后亚组分析,样本量有限(163例),统计效能可能不足。
- 总生存未见显著获益,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The results from the RATIFY trial (ClinicalTrials.gov: NCT00651261; CALGB 10603) showed that midostaurin combined with standard chemotherapy significantly improved outcomes in patients with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), compared with placebo. In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations. At a median follow-up of 60.7 months (95% CI, 55.0-70.8), the 5-year event-free survival (EFS) rate was significantly higher in patients treated with midostaurin than in those treated with placebo (45.2% vs 30.1%; P = .044). A trend toward improved disease-free survival was also observed with midostaurin (67.3% vs 53.4%; P = .089), whereas overall survival (OS) was similar in the 2 groups. Patients with AML and NPM1mut/FLT3-TKDmut or core binding factor (CBF)-rearranged/FLT3-TKDmut genotypes had significantly prolonged OS with or without censoring at hematopoietic cell transplantation (HCT), compared with NPM1WT/CBF-negative AMLs. The multivariable model for OS and EFS adjusted for allogeneic HCT in first complete remission as a time-dependent covariable, revealed NPM1 mutations and CBF rearrangements as significant favorable factors. These data show that NPM1 mutations or CBF rearrangements identify favorable prognostic groups in patients with FLT3-TKD AMLs, independent of other factors, also in the context of midostaurin treatment.
引用
- Voso MT, Larson RA, Jones D, et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020. PMID: 33049054. doi:10.1182/bloodadvances.2020002904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。